Ribociclib (LEE011) Rollover Study for Continued Access

This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02934568.

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationNovartis Pharmaceuticals Corporation

• Primary IDCLEE011X2X01B
• Secondary IDsNCI-2017-00789
• ClinicalTrials.gov IDNCT02934568